BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Les Turner ALS Foundation - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Les Turner ALS Foundation
X-ORIGINAL-URL:https://es.lesturnerals.org
X-WR-CALDESC:Eventos para Les Turner ALS Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20220313T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20221106T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20230312T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20231105T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20231106T080000
DTEND;TZID=America/Chicago:20231106T170000
DTSTAMP:20260421T093122
CREATED:20230621T160053Z
LAST-MODIFIED:20230621T160053Z
UID:18047-1699257600-1699290000@es.lesturnerals.org
SUMMARY:13th Annual Les Turner Symposium on ALS
DESCRIPTION:The 2023 Les Turner Symposium on ALS will be held virtually and in-person at Northwestern Memorial Hospital in Chicago on Monday\, Nov. 6. \nThe Les Turner Symposium on ALS has featured presentations from leading ALS scientists and clinicians\, as well as people living with ALS; plus research posters\, a Q&A panel and more. The symposium is free and open to the public\, with thanks to our generous sponsors. \nTime: Registration Opens- 8:00am \nSymposium – 8:45am – 5:00pm \nBreakfast\, lunch and refreshments will be served. \nIt will be held in person with opportunities to stream presentations from home. \nRegistration and Abstract submissions will be open in July. \nKeynote Presentation: Antisense based therapy for rare neurological diseases\nC. Frank Bennett\, Ph.D \nCurrently there are multiple genetic based medicines being pursued for rare neurological diseases including antisense technology\, gene therapy and gene editing technologies. Antisense oligonucleotides (ASOs are one of the more advanced technologies. ASOs are synthetic\, chemical modified nucleic acid analogs designed to bind to RNA by Watson-Crick base paring. Upon binding to the RNA\, ASOs modulate the function of the targeted RNA through a variety of mechanisms. Both protein coding\, as well as non-coding RNAs\, can be targets of ASO based drugs\, significantly broadening therapeutic targets for drug discovery compared to small molecules and protein based therapeutics. The approval of nusinersen (Spinraza™) as a treatment for spinal muscular atrophy (SMA) and the recent approval of tofersen (Qalsody) for familial ALS validates the utility of antisense drugs for the treatment of motor neuron diseases. The application of antisense technology as potential therapy for other rare neurodegenerative diseases and neurodevelopmental disorders will be discussed.
URL:https://es.lesturnerals.org/event/13th-annual-les-turner-symposium-on-als/
END:VEVENT
END:VCALENDAR